Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, will present results from a study that further demonstrates the ability of the Companys proprietary Discovery Engine, featuring the Companys Immune Repertoire Capture (IRC„¢) technology, to identify antibodies from treatment-responsive cancer patients that bind to non-autologous tumor tissue. The study will be presented at the Society for Immunotherapy of Cancers (SITC) 33rd Annual Meeting being held November 7-11, 2018, at the Walter E. Washington Convention Center in Washington, D.C.
Atreca has built a proprietary and unique discovery platform that enables us to discover, in a very efficient and industrialized manner from active immune responses, antibodies that can serve as the foundation of therapeutics, said Tito A. Serafini, Ph.D., Chief Strategy Officer and an Atreca founder. The results to be presented at this conference provide another example of what this Discovery Engine enables in oncology; namely, our ability to identify tumor-targeting antibodies in treatment-responsive patients with the potential to be developed into therapeutics designed to treat large patient groups. Our most advanced program, ATRC-101, which we anticipate entering clinical trials in 2019, is a product of this approach.
In the study, (Abstract #O3; Title: Anti-tumor immune responses in metastatic breast cancer exceptional responder patients) to be presented both as an oral presentation and a poster by William Robinson, M.D., Ph.D., Professor of Medicine at Stanford University and an Atreca Founder, Atreca researchers collaborated with researchers led by Joyce OShaughnessy, M.D., at Baylor University Medical Center and Texas Oncology. Atreca researchers investigated the properties of antibodies identified in the active immune response of eleven metastatic breast cancer patients who had exceptional and durable responses to systemic therapy. Of the patient-derived antibodies assessed, over 40% displayed specific immunoreactivity to breast carcinoma tissue from unrelated patients, but not to adjacent tissue, indicating that they bind to public tumor antigens. Multiple antibody lineages, predominantly of the IgG2 subclass, showed evidence of convergent antibody evolution across patients, and a subset of responder antibodies drove killing of tumor cells in in vitro functional assays.
Abstract Title: Anti-tumor immune responses in metastatic breast cancer exceptional responder patients (Abstract #O3)
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
- Concurrent Session 216: Role of B cells in Immunotherapy & Toxicity
- Date & Time: Saturday, Nov. 10, 6:10 “ 6:25 p.m. EST
- Location: East Salon ABC
Atreca also has a second presentation. Details are below:
Abstract Title: The identification of potent anti-tumor antibodies applicable for ADC therapeutics from patients undergoing immunotherapy (Abstract #P1)
Poster Display (for both posters)
- Date & Time: Friday, Nov. 9, from 8 a.m. “ 8 p.m. EST and Saturday, Nov. 10, from 8 a.m. “ 12 p.m. EST
- Presentation Hours: Friday, Nov. 9, 12:45 “ 2:15 p.m. EST and 6:30 “ 8 p.m. EST
- Location: Hall E
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics based on a deep understanding of the human immune response. We focus in a unique way on the immune responses of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, enabling us to discover and develop novel immunotherapies. Atreca is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.
EVP and Chief Financial Officer
Steinberg, 212-213-0006, ext. 318
Flamm, 212-213-0006, ext. 364
Grimaldi, 212-213-0006, ext. 362